A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions
Launched by EURO CTO CLUB · Jan 1, 2013
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥ 18 years of age with written informed consent
- • CTO in native coronary artery
- • a) Stable angina, or b) myocardial ischaemia in a territory supplied by CTO, and c) viability in akinetic myocardium (\<50% transmural late enhancement on MRI or normal resting perfusion scan)
- • CTO located in segments 1-3 (RCA), 6-7 (LAD), 11-12 (LCx)
- • target artery ≥2.5mm
- Exclusion Criteria:
- • AMI or NSTE-ACS within 1 month
- • Significant untreated coronary stenosis in a territory other than CTO
- • Patients with MVD and significant non-CTO stenoses where it is deemed unsafe to treat the non-CTO lesion first (e.g. Significant proximal LAD lesion with chronically occluded RCA)
- • Patient unsuitable for 12 month dual anti-platelet therapy
- • Any exclusion criteria for PCI or DES
- • Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure
About Euro Cto Club
Euro CTO Club is a distinguished clinical trial sponsor dedicated to advancing the field of chronic total occlusion (CTO) interventions in cardiovascular medicine. Comprising a collaborative network of leading experts and institutions, the organization focuses on innovative research and development to enhance treatment strategies, improve patient outcomes, and foster educational initiatives in CTO procedures. With a commitment to rigorous scientific standards and multidisciplinary collaboration, Euro CTO Club aims to drive breakthroughs in interventional cardiology through high-quality clinical trials and knowledge dissemination across the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toulouse, , France
Edinburgh, , United Kingdom
Bad Krozingen, , Germany
Darmstadt, , Germany
Massy, , France
Bordeaux, , France
Lagny, , France
Toulouse, , France
Bad Berka, , Germany
Bad Soden, , Germany
Catania, , Italy
Riga, , Latvia
Barcelona, , Spain
Barcelona, , Spain
Galdakao, , Spain
Madrid, , Spain
Brighton, , United Kingdom
Leicester, , United Kingdom
London, , United Kingdom
Patients applied
Trial Officials
Gerald S Werner, MD PhD
Principal Investigator
Klinikum Darmstadt, Darmstadt Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials